AstraZeneca Pharma India Ltd receives permission to Import pharmaceutical formulations of new drug for sale

AstraZeneca Pharma India Limited has received permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from Central Drugs Standard Control Organisation for the additional indication of Olaparib film coated tablets of 100mg / 150mg (Lynparza).

Through this approval, Olaparib film coated tablets of 100mg/150mg (Lynparza) in combination with Abiraterone and Prednisone or Prednisolone is indicated for the treatment of adult patients with metastatic castration - resistant prostate cancer.

The receipt of this permission paves way for the launch of Olaparib film coated tablets of 100mg / 150mg (Lynparza) in India for the above specified additional indication, subject to the receipt of related statutory approvals, if any.

While the aforementioned permission was received end of business hours on November 17, 2023, some time was spent in good faith for evaluation of the contents and conditions laid by the regulator in the permission.

Shares of AstraZeneca Pharma India Limited was last trading in BSE at Rs. 4649.05 as compared to the previous close of Rs. 4650.75. The total number of shares traded during the day was 249 in over 115 trades.

The stock hit an intraday high of Rs. 4724.30 and intraday low of 4638.35. The net turnover during the day was Rs. 1162754.00.

Source : Equity Bulls

Keywords

AstraZenecaPharmaIndia INE203A01020 ImportPermission PharmaceuticalFormulaitons